tiprankstipranks
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA

Vanda Stock Analysis & Ratings

VNDA Stock Chart & Stats

Day’s Range$9.83 - $10.12
52-Week Range$9.24 - $21.86
Previous Close$9.83
Volume503.91K
Average Volume (3M)570.68K
Market Cap$565.46M
P/E Ratio31.2
Beta0.59
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)0.32


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

VNDA FAQ

What was Vanda’s price range in the past 12 months?
Vanda lowest stock price was $9.24 and its highest was $21.86 in the past 12 months.
    What is Vanda’s market cap?
    Vanda’s market cap is $565.46M.
      What is Vanda’s price target?
      The average price target for Vanda is $12.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $12.00 ,the lowest forecast is $12.00. The average price target represents 19.88% Increase from the current price of $10.01.
        What do analysts say about Vanda?
        Vanda’s analyst rating consensus is a ‘Hold. This is based on the ratings of 1 Wall Streets Analysts.
          When is Vanda’s upcoming earnings report date?
          Vanda’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were Vanda’s earnings last quarter?
            Vanda released its earnings results on May 05, 2022. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.1.
              Is Vanda overvalued?
              According to Wall Street analysts Vanda’s price is currently Undervalued.
                Does Vanda pay dividends?
                Vanda does not currently pay dividends.
                What is Vanda’s EPS estimate?
                Vanda’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Vanda have?
                Vanda has 56,490,000 shares outstanding.
                  What happened to Vanda’s price movement after its last earnings report?
                  Vanda reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -2.041%.
                    Which hedge fund is a major shareholder of Vanda?
                    Among the largest hedge funds holding Vanda’s share is Hotchkis & Wiley Capital Management LLC. It holds Vanda’s shares valued at 10M.

                      ---

                      Vanda Stock Analysis

                      Smart Score
                      7
                      Neutral
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $12.00
                      ▲(19.88% Upside)
                      Hold
                      The Vanda stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Vanda Pharmaceuticals Inc.

                      Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Eli Lilly & Co
                      Bristol Myers
                      Johnson & Johnson
                      Evoke Pharma
                      Merck & Company

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis